All‐In‐One Biomimetic Nanoplatform Based on Hollow Polydopamine Nanoparticles for Synergistically Enhanced Radiotherapy of Colon Cancer

Gong, Liuyun; Zhang, Yujie; Zhao, Jing; Zhang, Yilei; Tu, Kangsheng; Jiao, Libin; Xu, Qiuran; Zhang, Mingzhen; Han, Suxia

doi:10.1002/smll.202107656

Cited by 60 publications

(44 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, considering the self-toxicity of MONs in hybrid nanozymes, surface modification is required to improve biocompatibility and hydrophilicity. Generally, polyethylene glycol , , hyaluronic acid, and various cell membranes ,, are often utilized to decorate nanostructures. Nevertheless, the above-mentioned modifications cannot exert additional therapeutic effect in vivo and usually fail to release the encapsulated components in response to TME .…”

Section: Introductionmentioning

confidence: 99%

Biomimetic Nanoarchitectonics of Hollow Mesoporous Copper Oxide-Based Nanozymes with Cascade Catalytic Reaction for Near Infrared-II Reinforced Photothermal-Catalytic Therapy

Wang

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Biomimetic nanozyme with natural enzyme-like activities has drawn extensive attention in cancer therapy, while its application was hindered by the limited catalytic efficacy in the complicated tumor microenvironment (TME). Herein, a hybrid biomimetic nanozyme combines polydopamine-decorated CuO with a natural enzyme of glucose oxidase (GOD), among which CuO is endowed with a high loading rate (47.1%) of GOD due to the elaborately designed hollow mesoporous structure that is constructed to maximize the cascade catalytic efficacy. In the TME, CuO could catalyze endogenous H2O2 into O2 for relieving tumor hypoxia and improving the catalytic efficacy of GOD. Whereafter, the amplified glucose oxidation induces starvation therapy, and the generated H2O2 and H+ enhance the catalytic activity of CuO. Significantly, the tumor-specific chemodynamic therapy (CDT) could be realized when CuO degraded into Cu2+ in acidic and reductive TME. Furthermore, the photothermal therapy with high photothermal conversion efficiency (30.2%) is achieved under NIR-II laser (1064 nm) excitation, which could reinforce the generation of reactive oxygen species (•OH and •O2 –). The TME initiates the biochemical reaction cycle of CuO, O2, and GOD, which couples with an NIR-II-induced thermal effect to realize O2-promoted starvation and photothermal–chemodynamic combined therapy. This hybrid biomimetic nanozyme enlightens the further development of nanozymes in multimodal cancer therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Biomimetic Nanoarchitectonics of Hollow Mesoporous Copper Oxide-Based Nanozymes with Cascade Catalytic Reaction for Near Infrared-II Reinforced Photothermal-Catalytic Therapy

Wang

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…Next, 66, 100, and 97 metabolites were screened between Ru-Sora + h ν and control groups, between Ru-Sora and Ru-Sora + h ν groups, and between Ru-Sora + h ν and h ν groups, respectively (Figure S22). Among them, differential metabolites between h ν and control groups and between Ru-Sora + h ν and h ν groups were used to eliminate the batch effect . By using Venn diagram for screening (Figure b), 49 metabolites were recognized as significant metabolites that were influenced by Ru-Sora + h ν and put into the MetaboAnalyst website.…”

Section: Results and Discussionmentioning

confidence: 99%

A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption

Lai

Luo

et al. 2022

J. Med. Chem.

View full text Add to dashboard Cite

The curative effect of sorafenib in hepatocellular carcinoma (HCC) is limited and sorafenib resistance remains a major obstacle for HCC. To overcome this obstacle, a new photoactive sorafenib-Ru(II) complex Ru-Sora has been designed. Upon irradiation (λ = 465 nm), Ru-Sora rapidly releases sorafenib and generates reactive oxygen species, which can oxidize intracellular substances such as GSH. Cellular experiments show that irradiated Ru-Sora is highly cytotoxic toward Hep-G2 cells, including sorafenib-resistant Hep-G2-SR cells. Compared to sorafenib, Ru-Sora has a significant photoactivated chemotherapeutic effect against Hep-G2-SR cancer cells and 3D Hep-G2 multicellular tumor spheroids. Furthermore, Ru-Sora inducing apoptosis and ferroptosis is proved by GSH depletion, GPX4 downregulation, and lipid peroxide accumulation. Metabolomics results suggest that Ru-Sora exerts photocytotoxicity by disrupting the purine metabolism, which is expected to inhibit tumor development. This study provides a promising strategy for enhancing chemotherapy and combating drug-resistant HCC disease.

show abstract

“…Hollow nanoplatforms are accompanied by mesoporous pore structures, thus it is not uncommon to see small molecule drugs encapsulated into the cavities [ 72 , 73 ]. Such novel nanoplatforms are able to serve as smart drug delivery systems (DDSs) to enhance the therapeutic outcomes of conventional chemotherapy and radiotherapy with reduced side effects [ 74 , 75 ]. Compared with the mesoporous nanocarriers, hollow nanoplatforms are more popular owing to the superior drug loading capabilities.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in near-infrared-II hollow nanoplatforms for photothermal-based cancer treatment

et al. 2022

View full text Add to dashboard Cite

Near-infrared-II (NIR-II, 1000–1700 nm) light-triggered photothermal therapy (PTT) has been regarded as a promising candidate for cancer treatment, but PTT alone often fails to achieve satisfactory curative outcomes. Hollow nanoplatforms prove to be attractive in the biomedical field owing to the merits including good biocompatibility, intrinsic physical-chemical nature and unique hollow structures, etc. On one hand, hollow nanoplatforms themselves can be NIR-II photothermal agents (PTAs), the cavities of which are able to carry diverse therapeutic units to realize multi-modal therapies. On the other hand, NIR-II PTAs are capable of decorating on the surface to combine with the functions of components encapsulated inside the hollow nanoplatforms for synergistic cancer treatment. Notably, PTAs generally can serve as good photoacoustic imaging (PAI) contrast agents (CAs), which means such kind of hollow nanoplatforms are also expected to be multifunctional all-in-one nanotheranostics. In this review, the recent advances of NIR-II hollow nanoplatforms for single-modal PTT, dual-modal PTT/photodynamic therapy (PDT), PTT/chemotherapy, PTT/catalytic therapy and PTT/gas therapy as well as multi-modal PTT/chemodynamic therapy (CDT)/chemotherapy, PTT/chemo/gene therapy and PTT/PDT/CDT/starvation therapy (ST)/immunotherapy are summarized for the first time. Before these, the typical synthetic strategies for hollow structures are presented, and lastly, potential challenges and perspectives related to these novel paradigms for future research and clinical translation are discussed. Graphical Abstract

show abstract

All‐In‐One Biomimetic Nanoplatform Based on Hollow Polydopamine Nanoparticles for Synergistically Enhanced Radiotherapy of Colon Cancer

Cited by 60 publications

References 79 publications

Biomimetic Nanoarchitectonics of Hollow Mesoporous Copper Oxide-Based Nanozymes with Cascade Catalytic Reaction for Near Infrared-II Reinforced Photothermal-Catalytic Therapy

Biomimetic Nanoarchitectonics of Hollow Mesoporous Copper Oxide-Based Nanozymes with Cascade Catalytic Reaction for Near Infrared-II Reinforced Photothermal-Catalytic Therapy

A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption

Recent advances in near-infrared-II hollow nanoplatforms for photothermal-based cancer treatment

Contact Info

Product

Resources

About